Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumors
Cases in which toceranib was used to treat dogs with anal sac anal gland adenocarcinoma, metastatic osteosarcoma, thyroid carcinoma, head and neck carcinoma, and nasal carcinoma were included. For dogs experiencing CB, the median dose of toceranib was 2. While these data povide preliminary evidence that toceranib exhibits CB in dogs with certain solid tumors, future prospective studies are necessary to define its true activity. It works as a competitive inhibitor of ATP, thereby preventing receptor phosphorylation and subsequent downstream signal transduction.
What should I expect from his treatment? Thank you, D. Dear D. They occur primarily in older average 10 years female dogs.